• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真性红细胞增多症和原发性血小板增多症患者血浆中纤溶酶原激活物抑制剂1(PAI-1)水平升高与血栓形成有关。

High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.

作者信息

Cancelas J A, García-Avello A, García-Frade L J

机构信息

Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.

出版信息

Thromb Res. 1994 Sep 1;75(5):513-20. doi: 10.1016/0049-3848(94)90226-7.

DOI:10.1016/0049-3848(94)90226-7
PMID:7992252
Abstract

We attempted to determine if a hypercoagulability state exists in patients with polycythemia vera (PV) and essential thrombocythemia (ET). We studied the hematocrit level, platelet count, use of any antiaggregant drugs, thrombotic or bleeding accidents and plasma levels of antithrombin III, protein C, total protein S, free protein S, vWF:Ag (Von Willebrand's factor related antigen), thrombin-antithrombin complexes, D-dimer, fibrinolytic activity, tissue plasminogen activator, plasminogen and PAI-1 in 33 patients (19 with ET and 14 with PV). PAI-1 plasma concentration was significantly higher in, both ET and PV patients than in the control group, and were higher in those patients with previous thrombotic episodes than in asymptomatic patients or with previous bleeding episodes. Increasing age was associated to more thrombotic episodes while younger patients presented with more hemorrhagic complications. A linear correlation between platelet count and PAI-1 levels in PV patients (r = 0.44, p < 0.05) and ET patients (r = 0.30, p < 0.05) was found. Fibrinolytic activity in patients with ET was significantly decreased when compared to the control group. A hypofibrinolytic state could be an additional factor which could be used as a predictive index of the thrombotic or bleeding tendency in each patient.

摘要

我们试图确定真性红细胞增多症(PV)和原发性血小板增多症(ET)患者是否存在高凝状态。我们研究了33例患者(19例ET患者和14例PV患者)的血细胞比容水平、血小板计数、是否使用任何抗聚集药物、血栓形成或出血事件以及抗凝血酶III、蛋白C、总蛋白S、游离蛋白S、血管性血友病因子相关抗原(vWF:Ag)、凝血酶 - 抗凝血酶复合物、D - 二聚体、纤溶活性、组织纤溶酶原激活物、纤溶酶原和PAI - 1的血浆水平。ET患者和PV患者的PAI - 1血浆浓度均显著高于对照组,且既往有血栓形成发作的患者高于无症状患者或既往有出血发作的患者。年龄增长与更多的血栓形成发作相关,而年轻患者出现更多的出血并发症。在PV患者(r = 0.44,p < 0.05)和ET患者(r = 0.30,p < 0.05)中发现血小板计数与PAI - 1水平之间存在线性相关性。与对照组相比,ET患者的纤溶活性显著降低。低纤溶状态可能是另一个可作为预测每位患者血栓形成或出血倾向指标的因素。

相似文献

1
High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.真性红细胞增多症和原发性血小板增多症患者血浆中纤溶酶原激活物抑制剂1(PAI-1)水平升高与血栓形成有关。
Thromb Res. 1994 Sep 1;75(5):513-20. doi: 10.1016/0049-3848(94)90226-7.
2
Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症患者体外血块溶解减少,且释放出更具活性的血小板纤溶酶原激活物抑制因子-1。
Thromb Res. 1998 Apr 15;90(2):51-6. doi: 10.1016/s0049-3848(98)00005-x.
3
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.真性红细胞增多症和原发性血小板增多症血栓形成患者抗凝血酶III、蛋白C和蛋白S水平降低及活化蛋白C抵抗
Am J Hematol. 1996 May;52(1):14-20. doi: 10.1002/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9.
4
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.血小板活化与功能受损的悖论:血小板与血管性血友病因子的相互作用,以及原发性血小板增多症和真性红细胞增多症中血栓形成和出血表现的病因。
Semin Thromb Hemost. 2006 Sep;32(6):589-604. doi: 10.1055/s-2006-949664.
5
Fibrinolytic imbalance in essential thrombocythemia: role of platelets.原发性血小板增多症中的纤溶失衡:血小板的作用
Haemostasis. 1993;23(1):38-44. doi: 10.1159/000216850.
6
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.基于白细胞负荷预测真性红细胞增多症或原发性血小板增多症中的血栓和出血事件。
Thromb Res. 2015 May;135(5):846-51. doi: 10.1016/j.thromres.2015.02.023. Epub 2015 Feb 26.
7
Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.临床和实验室特征、血小板介导的血栓形成和出血并发症的病理生物学,以及原发性血小板增多症和真性红细胞增多症的分子病因:治疗意义。
Semin Thromb Hemost. 2006 Apr;32(3):174-207. doi: 10.1055/s-2006-939431.
8
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.原发性血小板增多症和真性红细胞增多症患者中血小板介导的红斑性肢痛症、脑、眼及冠状动脉微血管缺血和血栓形成表现:一种独特的阿司匹林反应性和华法林抵抗性动脉血栓形成倾向。
Platelets. 2006 Dec;17(8):528-44. doi: 10.1080/09537100600758677.
9
Laboratory investigations and prediction of thrombotic risk in polycythemia vera.真性红细胞增多症的实验室检查与血栓形成风险预测
Nouv Rev Fr Hematol (1978). 1994 Apr;36(2):183-5.
10
Altered plasma fibrin clot properties in essential thrombocythemia.原发性血小板增多症患者的血浆纤维蛋白凝块特性改变。
Platelets. 2016;27(2):110-6. doi: 10.3109/09537104.2015.1042967. Epub 2015 May 19.

引用本文的文献

1
Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.骨髓增殖性疾病的心血管表现:文献综述
Hosp Physician. 1999 Jul;35(7):43-54.
2
Cardiac Complications of Myeloproliferative Disorders.骨髓增殖性疾病的心脏并发症
Resid Staff Physician. 2001 Jul;47(8):32-38.
3
Platelet counts are associated with arterial stiffness in Chinese Han population: a longitudinal study.血小板计数与汉族人群的动脉僵硬度相关:一项纵向研究。
BMC Cardiovasc Disord. 2020 Jul 30;20(1):353. doi: 10.1186/s12872-020-01634-7.
4
Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.番荔枝乙酰精宁annonacinone的特性研究,一种纤溶酶原激活物抑制剂-1的天然产物抑制剂
Sci Rep. 2016 Nov 23;6:36462. doi: 10.1038/srep36462.
5
The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera.基因多态性与白细胞增多症与原发性血小板增多症和真性红细胞增多症患者血栓并发症的关联。
Turk J Haematol. 2012 Jun;29(2):162-9. doi: 10.5505/tjh.2012.03780. Epub 2012 Jun 15.
6
JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.JAK2-V617F诱导的丝裂原活化蛋白激酶(MAPK)活性受磷脂酰肌醇-3激酶(PI3K)调控,并与PI3K协同作用于JAK2-V617F阳性细胞的增殖。
JAKSTAT. 2013 Jul 1;2(3):e24574. doi: 10.4161/jkst.24574. Epub 2013 Apr 8.
7
Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.PAI-1升高的临床意义再探讨:一例原发性血小板增多症且纤溶酶原激活物抑制剂-1(PAI-1)水平升高患者的多发性动脉血栓形成:病例报告及文献复习
J Thromb Thrombolysis. 1999 Aug;8(2):105-12. doi: 10.1023/a:1008907001042.
8
Thrombophilia in ischemic stroke.缺血性卒中中的血栓形成倾向
West J Med. 1998 Dec;169(6):385-6.